Skip Navigation

JNCI Journal of the National Cancer Institute 1996 88(22):1635-1644; doi:10.1093/jnci/88.22.1635
© 1996 by Oxford University Press
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Rosenberg, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosenberg, S. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 88, No. 22, 1635-1644, November 20, 1996
© 1996 Oxford University Press

Development of Cancer Immunotherapies Based on Identification of the Genes Encoding Cancer Regression Antigens

Steven A. Rosenberg

Surgery Branch, Division of Clinical Sciences, National Cancer Institute Bethesda, MD

Correspondence to: Steven A. Rosenberg, M.D., Ph.D., National Institutes of Health, Bldg. 10, Rm. 2B42, Bethesda, MD 20892.

Tumor-infiltrating lymphocytes (TILs) have been grown from patients with metastatic melanoma and administered to the autologous patients to identify those TIL populations capable of mediating tumor regression. These TILs have been used to clone the genes that encode melanoma antigens. With the use of this strategy, we have identified six different genes encoding antigens restricted by multiple HLA alleles that appear to be related to tumor regression in patients. These antigens are now being used to develop immunization approaches for the treatment of patients with metastatic melanoma. The availability of genes encoding unique cancer antigens is opening new possibilities for the development of immunotherapies for the treatment of patients with cancer.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
T. Fukuyama, T. Hanagiri, M. Takenoyama, Y. Ichiki, M. Mizukami, T. So, M. Sugaya, T. So, K. Sugio, and K. Yasumoto
Identification of a New Cancer/Germline Gene, KK-LC-1, Encoding an Antigen Recognized by Autologous CTL Induced on Human Lung Adenocarcinoma.
Cancer Res., May 1, 2006; 66(9): 4922 - 4928.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Monji, T. Nakatsura, S. Senju, Y. Yoshitake, M. Sawatsubashi, M. Shinohara, T. Kageshita, T. Ono, A. Inokuchi, and Y. Nishimura
Identification of a Novel Human Cancer/Testis Antigen, KM-HN-1, Recognized by Cellular and Humoral Immune Responses
Clin. Cancer Res., September 15, 2004; 10(18): 6047 - 6057.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. K. Mendiratta, G. Thai, N. K. Eslahi, N. M. Thull, M. Matar, V. Bronte, and F. Pericle
Therapeutic Tumor Immunity Induced by Polyimmunization with Melanoma Antigens gp100 and TRP-2
Cancer Res., February 1, 2001; 61(3): 859 - 863.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
D. R. Siemens, B. D. Elzey, D. M. Lubaroff, C. Bohlken, R. J. Jensen, A. K. Swanson, and T. L. Ratliff
Cutting Edge: Restoration of the Ability to Generate CTL in Mice Immune to Adenovirus by Delivery of Virus in a Collagen-Based Matrix
J. Immunol., January 15, 2001; 166(2): 731 - 735.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Adris, E. Chuluyan, A. Bravo, M. Berenstein, S. Klein, M. Jasnis, C. Carbone, Y. Chernajovsky, and O. L. Podhajcer
Mice Vaccination with Interleukin 12-transduced Colon Cancer Cells Potentiates Rejection of Syngeneic Non-Organ-related Tumor Cells
Cancer Res., December 1, 2000; 60(23): 6696 - 6703.
[Abstract] [Full Text]

Home page
 JNCI J Natl Cancer InstHome page
U. S. Kammula, F. M. Marincola, and S. A. Rosenberg
Real-Time Quantitative Polymerase Chain Reaction Assessment of Immune Reactivity in Melanoma Patients After Tumor Peptide Vaccination
J Natl Cancer Inst, August 16, 2000; 92(16): 1336 - 1344.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Ueno, M. Toi, H. Saji, M. Muta, H. Bando, K. Kuroi, M. Koike, H. Inadera, and K. Matsushima
Significance of Macrophage Chemoattractant Protein-1 in Macrophage Recruitment, Angiogenesis, and Survival in Human Breast Cancer
Clin. Cancer Res., August 1, 2000; 6(8): 3282 - 3289.
[Abstract] [Full Text]

Home page
 JEMHome page
E. Jager, D. Jager, J. Karbach, Y.-T. Chen, G. Ritter, Y. Nagata, S. Gnjatic, E. Stockert, M. Arand, L. J. Old, et al.
Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101-0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1-Expressing Melanoma
J. Exp. Med., February 21, 2000; 191(4): 625 - 630.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Drexler, E. Antunes, M. Schmitz, T. Wolfel, C. Huber, V. Erfle, P. Rieber, M. Theobald, and G. Sutter
Modified Vaccinia Virus Ankara for Delivery of Human Tyrosinase as Melanoma-associated Antigen: Induction of Tyrosinase- and Melanoma-specific Human Leukocyte Antigen A*0201-restricted Cytotoxic T Cells in Vitro and in Vivo
Cancer Res., October 1, 1999; 59(19): 4955 - 4963.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. A. Rosenberg, J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. Sznol, S. L. Schwarz, P. J. Spiess, et al.
Impact of Cytokine Administration on the Generation of Antitumor Reactivity in Patients with Metastatic Melanoma Receiving a Peptide Vaccine
J. Immunol., August 1, 1999; 163(3): 1690 - 1695.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
J. A Smith and B. R Goldspiel
Cancer gene therapy update
Journal of Oncology Pharmacy Practice, March 1, 1999; 5(1): 7 - 21.
[Abstract] [PDF]

Home page
 J. Immunol.Home page
T. M. Clay, M. C. Custer, M. D. McKee, M. Parkhurst, P. F. Robbins, K. Kerstann, J. Wunderlich, S. A. Rosenberg, and M. I. Nishimura
Changes in the Fine Specificity of gp100(209-217)-Reactive T Cells in Patients Following Vaccination with a Peptide Modified at an HLA-A2.1 Anchor Residue
J. Immunol., February 1, 1999; 162(3): 1749 - 1755.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. J. Zeh III, D. Perry-Lalley, M. E. Dudley, S. A. Rosenberg, and J. C. Yang
High Avidity CTLs for Two Self-Antigens Demonstrate Superior In Vitro and In Vivo Antitumor Efficacy
J. Immunol., January 15, 1999; 162(2): 989 - 994.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
E. Stockert, E. Jager, Y.-T. Chen, M. J. Scanlan, I. Gout, J. Karbach, M. Arand, A. Knuth, and L. J. Old
A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens
J. Exp. Med., April 20, 1998; 187(8): 1349 - 1354.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
I Drexler, K Heller, B Wahren, V Erfle, and G Sutter
Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells
J. Gen. Virol., February 1, 1998; 79(2): 347 - 352.
[Abstract]

Home page
 JEMHome page
E. Jager, Y.-T. Chen, J. W. Drijfhout, J. Karbach, M. Ringhoffer, D. Jager, M. Arand, H. Wada, Y. Noguchi, E. Stockert, et al.
Simultaneous Humoral and Cellular Immune Response against Cancer-Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2-binding Peptide Epitopes
J. Exp. Med., January 19, 1998; 187(2): 265 - 270.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. S. Goedegebuure and T. J. Eberlein
Vaccine Trials for the Clinician: Prospects for Viral and Non-Viral Vectors
Oncologist, October 1, 1997; 2(5): 300 - 310.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. Jager, S. Gnjatic, Y. Nagata, E. Stockert, D. Jager, J. Karbach, A. Neumann, J. Rieckenberg, Y.-T. Chen, G. Ritter, et al.
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
PNAS, October 24, 2000; 97(22): 12198 - 12203.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.